amyris inc (AMRS) Key Developments
Amyris, Inc. and Squalan Natural Health B.V. Partner to Accelerate Development and Sales of Neossance Personal Care Products
Apr 9 15
Amyris, Inc. and Squalan Natural Health B.V. have entered into agreements for the production and marketing of Neossance Squalane-based personal care products. The partnership between Amyris and Squalan accelerates development and market penetration of skin care and personal care products containing Amyris's Neossance Squalane, which is produced from plant sugars. Under this new relationship, Squalan will market and sell Neossance-based products to retailers and consumers, primarily in the European Union. As part of the agreement, Amyris is investing in Squalan and will have an option to acquire an ownership stake in Squalan and the right to appoint a member of Squalan's board of directors. Squalan will continue to be managed by founders Leslie van der Meijden and Monique Hugen.
Amyris Seeks Acquisitions
Apr 2 15
Amyris, Inc. (NasdaqGS:AMRS) has filed a Shelf Registration in the amount of $200.00 million, Amyris use the net proceeds for working capital, capital expenditures, research and development expenditures, commercial expenditures, repayment of indebtedness, acquisitions of new technologies or businesses, and investments.
Amyris, Inc. announced delayed annual 10-K filing
Mar 16 15
On 03/16/2015, Amyris, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
Amyris, Inc. and Genome Compiler Corp. Enters Collaboration Agreement to Commercialize DNA Construction Software Services for the Pharma and Biotech Industries
Mar 3 15
Amyris, Inc. and Genome Compiler Corp. have entered into a collaboration agreement to integrate Amyris's automated lab services with Genome Compiler's online design tools and e-commerce platform to enable users to design and order DNA or other biological products seamlessly. This integration will provide a comprehensive solution from design to delivery of integrated DNA design and construction service, which promises to be more automated, less expensive, and more sophisticated than current offerings. Customers will benefit from Genome Compiler's software tools and Amyris's rich libraries of verified genetic parts, DNA construction and editing methods.
Amyris, Inc. Presents at Morgan Stanley MLP/Diversified Natural Gas, Utilities and Clean Tech Conference, Mar-05-2015
Feb 26 15
Amyris, Inc. Presents at Morgan Stanley MLP/Diversified Natural Gas, Utilities and Clean Tech Conference, Mar-05-2015 . Venue: The St. Regis, New York, New York, United States.